<SEC-DOCUMENT>0001193125-12-200840.txt : 20120501
<SEC-HEADER>0001193125-12-200840.hdr.sgml : 20120501
<ACCEPTANCE-DATETIME>20120501162014
ACCESSION NUMBER:		0001193125-12-200840
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20120501
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120501
DATE AS OF CHANGE:		20120501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		12800927

	BUSINESS ADDRESS:	
		STREET 1:		7 WELLS AVENUE
		STREET 2:		STE 34
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02459
		BUSINESS PHONE:		617-559-0033

	MAIL ADDRESS:	
		STREET 1:		7 WELLS AVENUE
		STREET 2:		STE 34
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02459

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d342611d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>May 1, 2012 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>GALECTIN
THERAPEUTICS INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEVADA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-32877</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7 WELLS AVENUE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>NEWTON, MASSACHUSETTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>02459 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(617) 559-0033 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see</I> General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;30, 2012, Galectin Therapeutics Inc. (the &#147;Company&#148;) entered into a five-year consulting agreement having an effective date of April&nbsp;11, 2012 (the &#147;Agreement&#148;) with
Scott L. Friedman, M.D., Professor of Medicine, Chief of the Division of Liver Disease and Dean of Therapeutic Discovery at the Mount Sinai School of Medicine. Under the Agreement, Dr.&nbsp;Friedman will advise the Company on its scientific
programs, clinical trials and the landscape of therapies for liver fibrosis. In addition to payment for past consulting services, the Agreement provides that Dr.&nbsp;Friedman will be paid consulting fees up to $36,750 for 2012 and up to $25,000 per
year for the term of the Agreement. Additionally, Dr.&nbsp;Friedman is entitled to equity compensation, subject to approval of the Company&#146;s Board of Directors, comprised of 7,000 shares of the Company&#146;s common stock and stock options to
purchase 50,000 shares of the common stock, 20,000 of which vest as of the grant date and 6,000 on each of the five anniversaries of the grant date provided the Agreement is then in effect. The Agreement contains customary non-disclosure, trade
secret, non-solicitation and work product protective provisions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing description of the terms of the Agreement does not purport to
be complete and is subject, and qualified in its entirely by reference, to the Agreement, a complete copy of which is herewith included as Exhibit 10.1 and is incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting Agreement between Galectin Therapeutics Inc. and Scott L. Friedman, M.D., dated April&nbsp;30, 2012.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Galectin Therapeutics Inc., dated May 1, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALECTIN THERAPEUTICS INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>By:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Thomas A. McGauley</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thomas A. McGauley</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May 1, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit Index </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting Agreement between Galectin Therapeutics Inc. and Scott L. Friedman, M.D., dated April 30, 2012.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Galectin Therapeutics Inc., dated May 1, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d342611dex101.htm
<DESCRIPTION>CONSULTING AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Consulting Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g342611ex10_1-pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 Wells Avenue, Suite 34 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Newton, MA 02459 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">O: 617-559-0033 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F: 617-928-3450 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSULTING AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HIS</SMALL> A<SMALL>GREEMENT</SMALL> </B>is made this 11th day of April, 2012 (the &#147;Effective Date&#148;) by and among
G<SMALL>ALECTIN</SMALL> T<SMALL>HERAPEUTICS</SMALL> I<SMALL>NC</SMALL>. (&#147;Company&#148;) a Nevada corporation having an address of 7 Wells Avenue, Suite 34, Newton, Massachusetts 02459 and its subsidiaries worldwide and Scott L. Friedman, M.D.
(&#147;Consultant&#148;) having an address at Box 1123, Mount Sinai School of Medicine, 1425 Madison Ave., Rm. 1170, New York, NY 10029. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Company, wishes to engage the services of Consultant, and Consultant desires to provide such services, upon the terms and conditions set forth herein; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Company (then known as Pro-Pharmaceuticals, Inc.) and the Consultant are parties to that certain Consulting Agreement dated
July&nbsp;7, 2008 (the &#147;Prior Agreement&#148;), which they desire to terminate and replace with this Agreement </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW,
THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereby agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>1. Work and Payment.</B> The Consultant shall provide the services as set forth and more fully described in Exhibit&nbsp;A (collectively, the &#147;Services&#148;) attached hereto and incorporated
fully herein as it relates to the Company&#146;s existing products for the treatment of Fibrosis conditions (the &#147;Field&#148;). All services performed under this Agreement shall be in the Field. Therefore all references herein (and in any
attached schedule) to &#147;Services&#148; shall be understood as references to Services in the Field. None of the Services shall require Consultant to engage in marketing or promotional activities for Company or endorse Company&#146;s products
and/or services. In performing the Services, Consultant shall not engage in the practice of medicine, function as the director or investigator of any research efforts, or use Mount Sinai&#146;s facilities. Any photograph, videotape, reproduction,
likeness or image of Consultant shall not be used by Company, its affiliates, subsidiaries or successors for recruiting, publicity, marketing, Company/product endorsement or promotional purposes. Any presentation Consultant provides in
Consultant&#146;s performance of the Services shall be of Consultant&#146;s own creation and Consultant shall control the content of such presentation. The Services shall be performed, unless Company otherwise consents, personally and exclusively by
Consultant, who shall have the title &#147;Clinical Research Consultant&#148;. Company shall compensate Consultant in the amount and manner stated in Exhibit A. The foregoing notwithstanding, Consultant may engage, or propose that Company engage,
one or more other persons to perform the Services (such as a contract researcher); provided, however, that (i)&nbsp;the Consultant shall directly supervise such other person(s) and (ii)&nbsp;the terms and conditions of any such engagement shall be
set forth in a written agreement acceptable to Company whether or not it is a party thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Nondisclosure and Trade
Secrets.</B> (a)&nbsp;Company&#146;s confidential and proprietary information includes, without limitation, information supplied to Consultant in Consultant&#146;s performance of the Services under and during the Term of this Agreement with the
legend &#147;Confidential&#148; or words of similar meaning, marketing and customer support strategies including, without limitation, website password and password-protected material, financial information, including without limitation, sales,
costs, profits and pricing methods, internal organization information, employee information and customer lists, technology information, including without limitation, discoveries, inventions, research and development efforts, processes,
hardware/software design and maintenance tools, samples, media and/or cell lines (and procedures and formulations for producing any such samples, media and/or cell </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
lines), formulas, methods, product know-how and show-how, and all derivatives, improvements and enhancements to any of the above created or developed by Consultant in Consultant&#146;s
performance of the Services under and during the Term of this Agreement and information of third parties provided to Consultant by Company in Consultant&#146;s performance of the Services under and during the Term of this Agreement as to which
Company has an obligation of confidentiality (collectively referred to as &#147;Confidential Information&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
Consultant acknowledges the confidential and secret character of the Confidential Information, and agrees that the Confidential Information is the sole, exclusive and extremely valuable property of Company. Accordingly, Consultant agrees
(i)&nbsp;not to reproduce any of the Confidential Information without the prior written consent of Company, (ii)&nbsp;not to use the Confidential Information except in Consultant&#146;s performance of the Services under and during the Term of this
Agreement, and (iii)&nbsp;not to disclose all or any part of the Confidential Information in any form to any third party, either during or after the term of this Agreement. Upon termination of this Agreement for any reason, including expiration of
term, Consultant agrees to cease using and return to Company all whole and partial copies and derivatives of the Confidential Information, whether in Consultant&#146;s possession or under Consultant&#146;s direct or indirect control, except that
Consultant may retain a single copy of the Confidential Information disclosed under this agreement for the sole archival purposes. The confidentiality obligations and use restrictions of this Agreement regarding Confidential Information shall apply
during the Term of this Agreement and for five (5)&nbsp;years after its termination or expiration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Consultant shall not
disclose or otherwise make available to Company in any manner other than as is necessary in the course of providing services hereunder any confidential information of Consultant. Consultant shall not disclose or otherwise make available to Company
in any manner, information received by Consultant from third parties as to which Consultant has an obligation of confidentiality. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) In the event that Consultant is requested or required (by law or statute; by oral questions, interrogatories, requests for information or documents in legal proceedings, subpoena, civil investigative
demand or similar process) to disclose any of the Confidential Information, Consultant shall provide Company with prompt written notice of such request or requirement so that Company may seek a protective order or other appropriate remedy and/or
waive compliance with the provisions of this paragraph. If, in the absence of such a protective order or other remedy or the receipt of a waiver by Company, Consultant is nonetheless in the written opinion of counsel, legally compelled to disclose
Confidential Information to any court of law or tribunal or else stand liable for contempt or suffer other censure or penalty, Consultant may, without liability hereunder, disclose to such court or tribunal only that portion of the Confidential
Information that counsel advises Consultant is legally required to be disclosed, provided that Consultant exercises its best efforts to preserve the confidentiality of the Confidential Information, including, without limitation, by co-operating with
Company to obtain an appropriate protective order or other reliable assurance that confidential treatment will be accorded to the Confidential Information by such court of law or tribunal. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Consultant also understands that Company may receive valuable information that is confidential or proprietary from third parties
(hereinafter &#147;Third Party Information&#148;) subject to a duty on the part of Company to main the confidentiality of such information and to use it only for certain limited purposes. During the term of this Agreement and for the same period of
time that Company is obliged to preserve the confidentiality of said Third Party Information, Consultant will hold Third Party Information in the strictest confidence and will not disclose or use Third Party Information except as permitted by the
agreement between Company and such third party, unless expressly authorized to act otherwise by an Officer of Company in writing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>3. Non-Solicitation.</B> The Consultant shall not, directly or indirectly, entice, solicit or encourage any Company employee to leave the employ of Company, nor shall the Consultant, directly or
indirectly, be involved in the recruitment of any Company employee, within a period of one year after such person is no longer employed by Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Ownership of Work Product.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Consultant agree that any and all ideas, improvements, inventions and works of authorship conceived, written, created or first
reduced to practice in Consultant&#146;s performance of the Services under and during the Term of this Agreement shall be the sole and exclusive property of Company and hereby assigns to Company all its right, title and interest in and to any and
all such ideas, improvements, inventions and works of authorship. Any works of authorship shall be deemed works made for hire under U.S. copyright law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Consultant shall execute all papers, including, without limitation, patent applications, invention assignments and copyright assignments, and otherwise shall assist Company as reasonably required to
perfect in Company the rights, title and other interests in the Work Product (as defined herein below) expressly granted to Company under this Agreement. Costs related to such assistance, if required, shall be paid by Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Outside Employment</B>. Company acknowledges that during the term of this Agreement, Consultant may be engaged by one or more
institutions and that Consultant may be assigned work with respect to such engagements. Consultant shall use best efforts to segregate work done under this Agreement from work performed for any other institution, or performed with Government funding
such that no obligations with regard to disclosure of Confidential Information or limitations on ownership by Company of any Work Product (as defined below) will result. Company may terminate this Agreement if in its sole opinion the performance of
such work will conflict with its interests. Company acknowledges that Consultant is a full-time employee of Mount Sinai School of Medicine (&#147;MSSM&#148;) and agrees that, in the event the terms and conditions of this Agreement are in conflict
with the terms and conditions of Consultant&#146;s employment by MSSM, including the terms of any grants or contracts administrated by MSSM for which Consultant performs services, the latter shall prevail. Consultant represents that to the best of
his knowledge there are no such conflicts as of the date of execution of this Agreement, and that if any arise during the Term of this Agreement, Consultant will immediately inform Company in writing and Company will have the right immediately to
terminate this Agreement in such event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Indemnification/Release. </B>The parties acknowledge that the services
performed under this agreement are investigational in nature, there is no representations or warrants by either party that the work requested or performed hereunder shall serve to any invention whether patentable or not, or if any that it would not
be dominated by any other patents or that would result in any marketable product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Consultant shall have no liability
under this Section&nbsp;6 for any Work Product created in accordance with detailed and specific design instructions provided to Consultant by Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Should Company permit Consultant to use any of Company equipment, tools or facilities during the term of this Agreement, such permission will be gratuitous and Consultant shall indemnify and hold
harmless Company and its officers, agents, directors, and employees from and against any claim, loss, judgment, expense (including reasonable attorneys&#146; and expert witnesses&#146; fees and costs) and injury to person or property (including
death) arising out of the use of any such equipment, tools or facilities, whether or not such claim is based upon its condition or on the alleged negligence of Company in permitting its use. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In no event shall Consultant be liable to Company for any indirect, special, incidental, or consequential damages, including but not
limited to lost profits or savings, arising out of or related to this Agreement or the performance or breach thereof, whether or not the possibility of such damages has been disclosed in advance or could have been reasonably foreseen.
Consultant&#146;s liability to Company hereunder, if any, shall in no event exceed the total amount paid to Consultant hereunder by Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) In no event shall Consultant be liable to Company for any damages resulting from or directly related to any failure or delay of Company in the performance of services under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Termination. </B>Company or Consultant may terminate this Agreement for convenience with ninety (90)&nbsp;days&#146; written
notice. In such event, Consultant shall cease work immediately after </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
receiving notice from Company and shall notify Company of costs incurred up to the termination date. Notwithstanding the termination of the Agreement for any reason, Sections 2, 3, 4, 5, 6, 8, 9,
10, 11 and 12 hereof shall survive. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. Compliance with Applicable Laws. </B>Consultant warrants that all material supplied
and work performed under this Agreement complies with or will comply with all applicable United States and foreign laws and regulations, including, but not limited to, the U.S. Food, Drug and Cosmetic Act, Good Clinical Practices and the regulations
promulgated pursuant thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. Independent Consultant</B>. For the purposes of this Agreement, the parties hereto are
independent contractors and nothing contained in this Agreement will ever be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venturers. Consultant is an independent Consultant, is not an agent
or employee of Company and is not authorized to act on behalf of Company. Consultant will not be eligible for any employee benefits of Company. Company will not make deductions from any amounts payable to Consultant for taxes. Taxes shall be the
sole responsibility of Consultant . </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Legal And Equitable Remedies.</B> Consultant hereby acknowledges and agrees that
in the event of any breach of Section&nbsp;2 or Section&nbsp;4 or this Agreement by Consultant, including, without limitation, the actual or threatened disclosure of Information without the prior express written consent of Company, Company will
suffer irreparable harm and will be entitled to equitable relief. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Limitation of Liability.</B> Neither Consultant nor
Company, its directors, officers, employees and agents, will be held liable for any direct, special, incidental, or consequential damages, in connection with, or arising out of this Agreement, or the services performed by Consultant hereunder even
if the party will have been advised of the possibility of such damages; save and except only for damages that are directly attributable to that party&#146;s negligence, or intentional acts or omissions, or material breach of this Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12</B>. <B>Use of Name</B>. The parties agree that except for accurately describing Consultant&#146;s affiliation with
MSSM, neither party shall use MSSM&#146;s name in a manner that would identify MSSM with any product or any commercial or other activity that would imply endorsement or support thereof by MSSM. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13</B>. <B>General.</B> The parties&#146; rights and obligations under this Agreement will bind and inure to the benefit of their
respective successors, heirs, executors, and administrators and permitted assigns. This Agreement and its Exhibits attached hereto and hereby incorporated herein constitute the parties&#146; final, exclusive, and complete understanding and agreement
with respect to the subject matter hereof, and supersede all prior and contemporaneous understandings and agreements relating to its subject matter. This Agreement may not be waived, modified, amended or assigned unless mutually agreed upon in
writing by both parties. In the event any provision of this Agreement is found to be legally unenforceable, such unenforceability shall not prevent enforcement of any other provision of the Agreement. This Agreement shall be governed by the laws of
the Commonwealth of Massachusetts, excluding its conflicts of laws principles. Any notices required or permitted hereunder shall be given to the appropriate party at the address specified above or at such other address as the party shall specify in
writing. Such notice shall be deemed given upon personal delivery, or sent by certified or registered mail, postage prepaid, three (3)&nbsp;days after the date of mailing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>14. Prior Agreement. </B>Except for such provisions in the Prior Agreement that expressly survive, the Prior Agreement is hereby terminated. Such termination includes any equity compensation that the
Company may have obligated itself to issue or pay to Consultant, whether or not issued or paid. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL>
W<SMALL>HEREOF</SMALL>, the parties hereto have executed this Agreement as of the date first set forth above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COMPANY</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSULTANT:</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>ALECTIN</SMALL> T<SMALL>HERAPEUTICS</SMALL> <SMALL>INC</SMALL>.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Scott L. Friedman, M.D.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Peter G. Traber</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott L. Friedman</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and President</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Professor of Medicine</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/30/12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/26/12</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit A </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SERVICES </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I. Consultant </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MEDICAL ADVISORY BOARD and CLINICAL RESEARCH CONSULTANT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Medical Advisory Board (MAB) Chair and Clinical Research Consultant. </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The objective of the
MAB is to have a panel of physicians, regulatory experts, and clinical trial strategists with extensive knowledge and experience working in various aspects of drug therapy and clinical trial development to work in harmony with Company management to
determine drug development strategies, particularly as regards to liver fibrotic disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. As a member and Chair of the MAB, and as a
Clinical Research Consultant, the responsibilities will include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluate with CEO appropriate individuals as to suitability for membership on MAB and for inclusion as principal investigators in eventual clinical
trials. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Meet on a periodic basis, as requested by the executive management team, to provide a review of current clinical trial progress and upcoming clinical
trial initiation plans. It is anticipated that most of these meetings will be conducted by teleconference or webcast, although, it is possible that a face to face meeting may be necessary under appropriate circumstances;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assist in the development of clinical protocols in liver disease and identify potential investigators. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ensure that the medical and clinical information provided by Company to health care providers, governmental agencies, and the business world is
accurate, and participate in associated meetings as required; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inform Company on new therapeutic developments occurring in specific areas of Fibrosis treatment or care that could affect the Company;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Make recommendations to the MAB of the type(s) of expertise and/or experience Board members should possess in order to broaden the experience and
knowledge base of the Board in order to provide Company with the best advice; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advise Company on how best to present Company&#146;s available research data in a format that will be clear and informative to the investigative
medical community; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advise Company on how best to present Company&#146;s available data in a format that will be clear and informative to the investment community.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>II Term and Compensation </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement Term. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to
Section&nbsp;7 (Termination) hereof, the term of this Agreement will remain in effect for five (5)&nbsp;years beginning the Effective Date (the &#147;Term&#148;). </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting Fees. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) The
Consultant shall be paid consulting fees for 160 hours of work for the fourth quarter of 2011 which included preparation and participation in a special meeting at the AASLD meetings in San Francisco in November. At a rate of $150 per hour, the total
amount to be paid to Consultant is $24,000 for the fourth quarter of 2011. The Consultant shall be paid consulting fees for 120 hours of work for the first quarter of 2012 which included discussions of scientific research, review of company
presentations and documents and consultation on indications for company drugs. At a rate of $150 per hour, the total amount to be paid to Consultant is $18,000 for the first quarter of 2012. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Annual Compensation. The Company shall pay the Consultant twice annually on June&nbsp;30</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> and December&nbsp;31</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> consulting fees based on the number of hours expended in the
previous six months at a rate of $150 per hour of effort. For 2012, the July1st payment will be for the second quarter of 2012 only. The annual total compensation for the final three quarters of 2012 shall not exceed $18,750 and for subsequent years
of the contract shall not exceed $25,000. beginning on January&nbsp;1, 2013 and thereafter on each subsequent year provided this Agreement is in effect , or a pro rata of the annual fee amount based on months of service if termination occurs prior
to such anniversary. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. Equity Compensation. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Stock. Not later than 30 days after the Effective Date and subject to the approval of the Company&#146;s board of
directors, and provided the Consultant shall have acknowledged by his initials below that he is an accredited investor, the Company shall issue to Consultant 7,000 shares of its common stock (the &#147;Shares&#148;). The Consultant acknowledges that
(i)&nbsp;the Shares are &#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act of 1933 and may not be resold unless registered or in a transaction exempt from the registration requirement, or pursuant to Rule 144,
if available, and (ii)&nbsp;receipt of the Shares may constitute taxable income. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
SF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[please initial] The Consultant represents that he is an &#147;accredited investor&#148; as defined in Rule 501 of Regulation D under the Securities Act of 1933. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Options. Not later than 30 days after the Effective Date and subject to approval of the Company&#146;s board of
directors, the Company shall grant Consultant 50,000 non-qualified stock options, exercisable for ten years from the date of grant (the &#147;Grant Date&#148;) at an exercise price equal to the Fair Market Value (as defined in the Company&#146;s
2009 Incentive Compensation Plan) of the Company&#146;s common stock on the last trading day prior to the Grant Date, which exercise rights shall vest as follows: (A)&nbsp;20,000 shares as of the Grant Date, (B)&nbsp;6,000 shares on each of the five
anniversaries of the Grant date, provided this Agreement is in effect on such anniversary, If this Agreement is terminated prior to the expiration of the Term, exercise rights shall terminate as to any vested options that have not been exercised
within 12 months after such termination date. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">d. Travel Time for travel requested by Company; travel expenses for meetings
requested by the company that Consultant attends in person, $160/hr., to a maximum of $1280 per day. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenses to be paid/reimbursed:
Reasonable travel and accommodation, and miscellaneous expenses, such as telephone, courier, etc., in connection with the work performed under this Agreement upon submission of an expense report and documented receipts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Method of Payment: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All payments made pursuant to this Agreement shall be made to Consultant. A Federal tax ID or social security number must be provided to the Company prior to payments being disbursed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d342611dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g342611ex99_1-pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Galectin Therapeutics Announces Long-term Engagement of Dr.&nbsp;Scott Friedman to Advise on Liver Fibrosis Programs </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>-Renowned Physician and Researcher in Liver Diseases- </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Newton, MA &#150; May&nbsp;1,
2012 &#150; </B>Galectin Therapeutics Inc. (NASDAQ: GALT) (&#147;the Company&#148;), the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for therapy of liver fibrosis and cancer, today announced entering
into a five-year consulting agreement with world-renowned expert in liver fibrosis, Dr.&nbsp;Scott Friedman of the Mount Sinai School of Medicine. He will advise the Company on its scientific programs, clinical trials and the landscape of therapies
for liver fibrosis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Dr. Friedman is one of the world&#146;s foremost authorities on liver fibrosis and its therapy, whose work and
perspectives have shaped the world&#146;s current view of the disease,&#148; said Dr.&nbsp;Peter Traber, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics, Inc. &#147;We look forward to his guidance and
contributions as we develop a new class of therapeutics for the treatment of liver fibrosis.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Galectins appear to play a
significant role in the pathogenesis of liver fibrosis, a potentially fatal disease with no efficacious therapies,&#148; commented Scott Friedman, M.D., Mount Sinai School of Medicine. &#147;However, preclinical data on the Company&#146;s galectin
inhibitors show very promising activity in the prevention and even reversal of liver fibrosis. Based on the potential of galectin inhibition to treat fibrotic liver disease, I am enthusiastic to join with Galectin Therapeutics as we work to develop
potential new therapies for this highly prevalent and serious disease.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Friedman is Professor of Medicine, Chief of the
Division of Liver Disease and Dean for Therapeutic Discovery at the Mount Sinai School of Medicine. In his recently appointed position as Dean, he oversees an innovative program of drug discovery and development within an academic setting in
partnership with biotech and pharmaceutical partners, a novel program within an academic institution. Dr.&nbsp;Friedman has performed pioneering research into the underlying causes of scarring, or fibrosis, associated with chronic liver disease,
which affects millions worldwide. He was the first to isolate and characterize the hepatic stellate cell, which is the key cell type responsible for scar production in liver. He has written definitive reviews, delivered authoritative lectures and
consulted extensively to industry, the NIH and FDA on the pathogenesis of liver fibrosis, including therapeutic approaches. He will be awarded the International Recognition Prize from the European Association for the Study of Liver Diseases in
Barcelona on April&nbsp;20, 2012, and is the past recipient, in 2003, of the International Hans Popper Prize awarded to the outstanding liver researcher in the world under the age of 50. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g342611ex99_1-pg002.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Galectin Therapeutics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company&#146;s unique understanding of
galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press
release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words
such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those
described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to
adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence
on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue
reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maureen Foley, 617.559.0033 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Operating
Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>foley@galectintherapeutics.com </U></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g342611ex10_1-pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g342611ex10_1-pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-0#<`P$1``(1`0,1`?_$`-@```$$`P$!````````
M``````D`!P@*!08+!`,!`0`!!`,!`0`````````````%`P0&"`$"!PD*$```
M!@$!!P(#`P,+#1$!```"`P0%!@<!"``1$A,4%0D6%R$8"B(C)#$E&4%18=$R
MDC.V=W@Y0E.U)D:&QC>W.*AI*G&14H)#DT34-E:6UE>76&@I21$``0,#`@0#
M`P0*#PD``````0`1`A(#!!,%(3$4!D$B%5$6!V$R0B.!D;'!8D.S)!<(<:%2
M@C-CPS1TA"5%=38WX7*T-64F1Q@H_]H`#`,!``(1`Q$`/P"P5YR?-8P>*^O(
M37=4Q)#<VMS4$+MM%U";U:MN9D:IP"P%6-.F]H-*>5C(*0&A0-#6G&0I?W,)
MA)1I12=4<41-EIH\+%C:BXBRW1YL]0]QZQ+VF:4J2.>FQ!:$IK;271ICJ`:L
MJ$L=:U&ZPQDF3VQ%*<$+ERC(FPTXO("DY^`=:I(IA&>%#1I7S<I<-'&+8T#6
M>02(<?LO2O;$YC!21P*"88C]655*'R4TS9;")4+`E;>^,"L*HKB!@PH0L&!(
MAI5WY$/(2W>8G05XN=5[8AC,QB!.J&>VM<U6D%,5.:XJ=!IZF!VG^P6R%+<+
MW."O#7+(^Z'25D+5&(T$D:P82&C3;BP$5J;8B6Q$MB(2GF7HBR;+T47S:U0Z
ML=3FERQ].U`WE:<354#968+'IJZ1.%&S,IFL]N):53B_M)@(B)(G&D6-ZE&%
M<>,!@LBX=B(=7TD5A3RTO%C)IQ9<UEMA3)[U<W4H=Y7.)&\2N2.9N8W60N->
M]OJQ<XJA8R+.[C,SNWY_7V(K0&Q$MB);$2V(EL1+8B\3<Y-SND+7M*]$YH#A
MGEE+6Y40M2&C3'FI5("U*8PTD8TZH@98\8%G(#`"#G=G&<;$3%W_`*J=/.EE
MLBCQJ"M:,5:W3=_Q&(JHD0UN>\/&"@GGE$$MR-<>2C0$#"-4K-"6C2`&$1QI
M>!!SFRS=QPMOC&6;<C;C,L'\3]CV>)Y#Q63=M=G=S]XW;UCMG"O9EW'MZEP0
M;RQ=@340"2>$8AY28T@L4_A)Q*DDI0G-*4)U!19Q!Y)@#23B308,*-*-+R(!
MA1@!8R$6,YQG&=^-KT$$..2QJ491D8R!$@6(/,%?78N$MB);$0?O,MJ5OK3)
M1=32;3U+U\1F,MNILA:H;9'&&4+WM"X1.4JTK&C;'YH>2S5:YY1IL$A(*PH,
M-X2PYSQ9#G!._MVW7:-LL7=HF895S)C#A$2)!C(L`1+B2!R#K;+]4#X<=B_$
MOOS<]J^(.+'*V7%V6YD@2O7;$;<X7[$3<E.U<MD1C;G.JJ5(#R/)QF=$]+>1
MJ11MBL76CJNE#&I=TI#FEHZ#0BIFES;$QY834Z>?S'T*J4IW(8,XR<W-@2AI
MLYX!K,CP,`:_;^W]US@,GN#-D">5F$+0(_WYB!X_@PY?NO!6/QG[L_5ZP=PO
M]O?!OMBQ=MVI&$MRR<K.N0F1P)Q<<Y(!@_S;M^JOF+(BTB1=RNFF8ZZXC+Y;
MU:-,@3B+2F,KU/XJ@?<'_`L)9[<L=2%O4&"Q^3)>,Y%^IMF@X!EJX2Y)Y.F,
MU%5)J,F;&MDFF;4V]UQ*A)A+FR-/\>@DLKE^XRPF$)0+UD36R2/X5!SO`J+4
M+20[\?A\X^."X5;JQ?(-Y**DFLAKJQ[6>HI,HNN$@>65Q@5;8-),X<&$*DIY
M<3&F<&Q>G&$Y*J(&,A00,(P"R'.Q%I7Z4S7C_P"O*K_P+6__`)2V(LQ^E"UU
M>G.N]]575>HNBYOH>N=_3=IZCE</I/@W<[[6_=O_`&=VQ$!S21<)OE=^JQ@5
MPS`XR001MU$V'+*W;5XLJT3+6.E:"S1XII&D3"QE,F*RXP=N<SP@#@!K@K/.
M%C(S19R1=0G8B6Q$/S4!H@(N+7=H#UL-+TPL+YH\#J2892B5MJHYZGL'O:H7
M&$-S$W."88"$ID5F(D[D#J<#+P0:J"7N,-WY(IZNCHVLC:XO3TXH6AG:$*MT
M=G9T5IT#:UMJ!.8K7.+BN5F%)42%$E*&8<<8,)998<B%G&,9SL1"7@OF-IV^
MQR]RT<::-9FMFNH2_.D6=;KT^U9!$-,NDD9.'#PRPJ=WC:],I+"4MPQ@P88Q
M%."7<8`03<@,+$(B<W1IY7-)NMBSK'H&$JK)J+4[4(3C[)TO:C("OJ2](NWI
MQHRSW?,77JG)JD#.0)Q3Y,4M+@X%DEJ2##,A*4$#-(G;\CW]'EKR_F8ZHO\`
M(?.=B(#OT<W]$0X_SLKH_BU6&Q$?;5WKDTWZ((M%9#?<S7('FQ9&1"ZEJ^%1
MI^L2X[DFRLQ.0EB-55;#T+M+YD\F*%I`#,ITW2I,GE94G$A,`+)%#"Q/-!3.
MG[T@^:OM+6N'1O5,W>VR.--\WQ3,/4T\T/;V=DEE;9Y(:<M.VG>ME3H+'W>'
MYO;PXQ@>1B!RC>`B+LR/;-)69HD<<=FQ_CS^V('MB?65>E=&=Z9G5*4N:W9I
M<T)IZ)Q;'%">`X@\D8RCBAA&`60YQG8B'WJ-\H.FC3W<;?IG;$5KZDM5+BSX
MDF=,NE6O5=Q6XQ1C."!>IIX2F7,T+J]AR%60(*B3/+0$PM048#B+&$62)HFG
MS.Z98]>=<:<=4=;:C]"-JW.8%-3"+5W7D:B$.M9QRX(FK+/$+/KB?6G6N'HI
MR<DQ`TC@ZH#PGJDY>0\:@@)A%IWF6\N"?Q>T).)+'J"O>V[040'#I"Y/'ZCF
M2W3E`7F2.ZJ'Q=ZNB\,-F('&DR&2\H>60*LQY<<F)B0%$@6%J@$4./"/Y(*O
MC?C7T25Q+:PUJR:>*X7A)(9G&-$6J6;UV\2F7V%)'%RD!%KQ:JW.OG1E4.CT
M,]4Z$.`T1/W@C#`X`/A(EY;O*GX,F=V34[KF46A:5@4;.I*8V5Y"*AO1F>B9
M,Q*`L4N9FJ:.#=6]?RAB<#4A:=9@E_/;%."RA<S=@L>T=N.TX&ZQA'.A6+9<
M<2.?,<".!8./D68]G]^]U=AW\C([7RCC7<FT+=SR0F"`7B6G&0$HDDQD`X<^
MTH]<\U"U12FG?&H:8%RIEJ5DAD4DHTT4KN:6'*6]AD0&=*Q(D-?5<PS*6.:@
MD3NG*-*;T:H"8&!&#$$@L9H9```,.06(3G.Y,W+A)G(DDGF2>))^4H9VD_Z@
M;QMZPY;J)C]=6),87'M,%<DVG9UF75#\51`28GF3$P]8:VGR=V)E(7%ND*Y&
ME&E7-2$\Y0M()("<<+)>.5U6JW;]0%ILT^,Y%BVAI&\E<;T[*G-N;T^J5ZT<
M2>+4@8G=U&$S2]FJ9K(8S8C>R.PQ@RC-5QU.8LP8#!!9HA!#DB,'1=ZU'J8J
M2"WM1$[8[+J6RF0J0PN:1TXTQM>&X9QR4[&2E)2=<WN+<O3&I5B-442K1*R3
M2#RRSBQ@"1>F?5!";+DU5RB8MH7=73LQ4V!"TBD)9J!),#(\[1I`^'D&%CP<
MK94+XI,29^')59`<'[98,XM,G!Q\N[9O7XU2L7*X/R$J3$2_9`D6]AX\PLCV
M3NK>>W<#<MOVBZ;-K=L,8N08N)2Q]6W>E:!!X1N3M0$_W4`8'RR((.O+UKKG
M,1E6-+-/R)PB8B6)"[6Y*F-4:@?S\2!/U+1!FIS3"+5-20UG&!6XFD"`<>6J
M)(",(.>$R[6.("4`IZS;?7.R*L:VE]D.3402X/B:(QU?(UB%.M.,)(6N0$)"
M@THM4H+$$)AG[L>,_'.=^Q$3[2Y._)[I0CLLB,)T]7/)XJ_,ZI/'XY-J[FCN
MSP.2&B+Z>4QA-@@!J?!)?,P<VX,`@5#$`8PX$#.1D42)[IQUXVE+7F>6+1FH
MJ93"0*.I=W]\@,G5+5(@XX"2"\80`(1($96,%ITQ`"TZ<H.`%@"'&,;$6H?)
MCJ[_`/C)>7_MO)?^H[$6<^3?5KZ7Z;Y:;OZCU-U')]N9)S.1V;E<[@Z'BY7-
M^SQ?DXOAL15\_IWVARTU?4(4=4UCD'-4GBDXU2T4^$N`1DJ$TQ;JIM:-83GA
M,X18/5O#1RP[_P!T(W&[?OQL1=9K8BC#J@=]9#-&H^IT:P33E/I9W)?F6->H
MVR+&K5F+9BV\0V[,9=*[K:R5*MW4.F,%F@5D)B"R<\6!B%]G8BJ&QSZHGR)R
MG7`'QY-7C:HW.IS%X/-`*(P?J"E13&CG$==U[6^JU,D##!H?2S60UJ%YB\OC
M`)O*R<`(]X0Y(K2SO0]UZS]%=SZ<=?+17E4R"]8S,:WE).D:SYA*$+37\C:T
M:1.K:9I9%<0]>&4"--5%JTYK,H;3"`A`+G%FFEX(F9K9[T`^$_3-0^C!ML=T
M1$1]M>F^HJD3)G6X=4%UOCZ_O,JDCO':GK".KYW-W9\D[PJ.4*&YD*:T63,`
M$),07CA(JN,AN>96-]7WHNLA52-IZ9U,ZI\EI,A-M>C&ZQI/#SJ#OI`CDLPC
MT'E$N2QD;\C0%%%M3BLR[)"T)75$D#X2@$5R#R/?T>6O+^9CJB_R'SG8B`[]
M'-_1$./\[*Z/XM5AL1"STT7?JG\A7U.NL.UZC2T?-7K0_"[KK&@8QJ2?K`::
MXKV%U]8#!0[G((:"O6&3.I,UDCK('ER,$81@D7>%.<FX$4F#@BL,ZX=+GECU
MUZ3[OTDV"U>-6,Q*\(?F*.<F;)CJ:?76-&DNC:]M<A:&MSK)*@5.S([M)"E+
MS3`A`>4`?QX=V2+0*-AVIWP8>"B\V^^+3@E[6-I$K6XW^CW^*E211'D;$YD%
MG5%#7KU<WM[HK21JP7XPG)7+R22S\A,5GA*P$)%%+Z0VNP/>AV_=9<^<5DXU
M$:KM4]AKK/M.1G]SETD;(2D92&Q"YNYX1+#09E;Z^.0PY%PB.<-^[<`&,$1R
M-??C#TD^2QLIAKU3Q.12`-#6%[BP!;%I4X1-R3K5(4!;['G%8@"8-9%Y06TH
M\+R`X*4"RD*$2>2,/%DB@7]4#G./"!K0QC.<8R71F,XW_EQ\Q-49W9_7QOQC
M8B>_Z?C^AF\?7\AI7\;I1L1!`^MI:&T[0WI%?S4:<;PVZK5S.A<!$E"5)6U\
MIV>K'9&2?D&3BTZ]5'T0S0!%@(Q)B\BQG(`YP16]J)_Q(4W_`"55Y_%%HV(J
M-WBET]U'</U2/EB66-$4<F24M,KRN&!QY:(>8HELM+?L&:V:8.\:QGM$@=HP
M.2JUS4)84<%N=A%KR0A6$$'%$5P;R:,+-)_')KU9)`VHW=J6:.-2HU"%<06H
M3F&HZ<F*Y$=RS0B#@]&N3%G%#W<19I81AS@0<9V(@?\`T>3TYNGB`+1+U9RE
M+'-4=VLS,2:,0P(&T]N@<A-2$8%G."RAO#\K/SC&[',.%G\N<YR16H-B*F/Y
M38B^Q/7+<YKT4=@B7F1291]48$>"UK"X1-G:RAIQCQN,+0N3,J2"W?`(T^<;
M$6Y^,35[4ND*<6Q(K:!+!M\TBD;96;$38@/I_6-+PY+E>5A0UZ#"<KD*P<`M
MXN+._'PW?$B-=%_,5I+F4GC</CK5=#C()8_,\:8D!->$9,6.[XX)VUO3AP&0
MBSC!BI2'`L[OLAWYS\,;$15]B(;^JCRFZ8-'MI`J"W2K-'+AQ9FEX<Q.%E/K
M3VA\5.J-#CKS'E!^+P<SG<9?!]C'#G?G?MB.]=[;)L&;T&?K=10)>6%08NW%
MQ[%L1\+_`-6'XG_%WM@]V]HC;O2!E7,?Z_)%J>I;C"4O)1+RM<BQ?CQ]BC[^
MGCT,=L[MT]W])W+M7^+5/S>JZ/KOW'J;^"Y']5O_`'7PVBOTG=L4U_G#.W\'
M_M6>_P#HS\<NJZ1MFU=+4_GH:FJGGI\W\/8JXWU"7BWU"Z1M<,'\XVA"%+YL
MAB5CP.Y=0E?QM`J<'.$6-7:QK//LTQD;2S5KE5UCLS2%/*A)RS#&U6-0M/WI
MEAIB7T-:=*WMX^_(;II\D^GZ,7]IQFS:])%Z!O+G<`4."/,]J28'I`&N4(G[
M$69A6UNC>HXPD*,E]&Y)PA4I##2#`#R12YG<\A-7PV2V)9$LCL$@<-:%C_*Y
MC+7A"P1N.,C>5DY:Z/+RYGID#>B3EXWB,,&$/Y,?ESC&Q%R_O&_:[=JY^J>8
M-4]8QZ0N=/6-K'U)S&-2;,?=,-H8JX5;;R:(.SPI$CZ=G6/:`E*JP2>(!I1I
M^`9QQ8W;$5]/S:ZU+.\?GC/U):GZ8:4[C:<3:XC&(0O<&X#JT1)]LB<QROTT
MY=F\X!J58GB`9&)<22H`-,>L*)*."(H8PY(AO?3*0REG7Q^&>0^P[";[:U=Z
MBI5:KSJOU)6E)$[]8,7%#9P^M#96;O+I$K-5PF'1^(-+>[B;\&)$AG<`J<AR
MGPDP41!\MC4=3U__`%>^A:UZDE>9;5ZN"M,)CMB%-#NUPR>.:*J]0T:.=ZVD
M#RC;T%@PLZ3K!-B5]:1*FEP7)CRTB@_!619(K;.M^\JHM#QR^3)S@TT:WMKJ
M[3[K+IV<NF`JT#8R61"*:E;=+(OW!S3(TC@J8G9P`B/-2C.3A7!,3X,R<48`
M)$&CZ-YP1*O$C($:=40<K:]7%Q$."8LTL1Z,U3$*J6IPJ"@BR,K)R4\(P\6,
M<0<[\?#8B&-IQBBKP]?536RAO(7HNAO(F&ZL4O9[QG*&$.PKYFS%;,=9\/2C
M`$1+K'[;8_22HH8PC3J5J4\80)E1)@R*_>H4)T:<]6K/)2I4I)JA2I4&@(3I
MTY`!&G'GG&B"62226'(A"%G`0AQG.<[MB(4VH;$'\PGC*UAUQI_4O0HU<,2O
M"F*CL&2-R=HB%E2^OUJMJC=B01R`X*PR&G7RR8^$A`^;B"W%(F-4D`$G$2<:
M1`P^D`U&(HK0VICQL6\0?7.IS3??DQG"BK)<'+)+S(?*DC$QR@A.R+LEJU"N
M!6%&UA+K@L(L)@NB(0OLG!SDBMA:C;_KK2W25C7U:C@<BAE<1U6]K$J`!*E_
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M?K1>@7)#0'I5B)9"V50E5ICB\Y`<G4$&!&`0<YP(.<9QL14R/"K(6,WZHGS3
M)B75"<:\->H@EK"6J(%UYS+J3JH#J2DW&;U)J`18L&!!Q9!P"SG=C&<[$5L7
MR1+4;?X\->"QP5ID*0G1MJ;YRI8>4F3%<REIJ4#F''"`6#C-&$.-^?B+.,8^
M.=B("'T;3BA5^)63H4ZH@Y8U:N[@(<4H#2Q'HS%4*J9:F"H*"+)A//2GA&#B
MQCBQ^3?NV(B,^9GR:J/%8RZ++\?D"Y\I>9ZJTU0:@&%J2E*WLRL)555B.9TE
MCA(\8&?(8/(6!"ZDI@C+Z\E,<DX@948,`1/OJ#TZ:;_*;0U=VW5%FQQY+<6'
M,AI:]H*<DDC(Y,CP$!Q[(]$$G)S'-A4*R>%4B,&G7M:XL>-Q1P3R1D00WOPU
MZVFQ\.:VQEK62-@#Q%D29OL!*@;#B<"W!4F(7EO0/B?`@YWY!A,8(.=^-^?A
MG)$5C0;XKVC3))$UV7?)6":6>QI5)L9:V8)^(-7PCTAA2U\[@[D(U3[(RD9I
MA0%1A"9,B`(8BP#,R$X!$^.B[R94=KTU":R*FT[.*";U[H_7U)#G>WVAP+71
MNP;#GI=C*I6AA9Q'$0Y12%!AJ9&!T`(1+DM-4"39&E*)4*"*NQY[?\^]+_(1
M7/\`9Z=[:Y_$_P#S0?Z-;^[)?9;]1#_0R?\`CN7^2Q4(#^X;^_;_``<VP'\3
M^_\`O+;K^_?ZC_++IDB#@6,A%C`@BQD(@BQC.!8SC=G&<9^&<9QMN4OS7H4E
ME>$[QRV!9JR[HY23OIZNIP&H-<+5TE6G:.EF7N)JL>#5A[H*CI="F5V4+C\<
MP\U4C.-/,^T,0A9W[$7L.\-NB.6+&I;?;9>^KS#$L*7LK-K#U0Z@M1\);U9&
M<Y(/Q6EDV(\5JN.*W[@C5M"@S&/ZK8B)1#81"ZZCS=$:^B$7@D3:"0IVF,0U
M@:8Q'FQ.`.``(;F5D2(6U$2$(<8P$LH(<8Q^38B\%E5K7]QP&7U9:L.CM@UQ
M/F%PB\SA4L:TKU'9*P.I`DZ]K=FQ:6:G4ICRA?JXX@"Q@0<X$'&<$0@Z:^G<
M\1%%S%PE\,TK%N12]Y(?LP.?VE;MCU*6YI#\*$)ZFIYK.7NOY!VXS&.FP[M[
MATV,8P5P[MB*1VM7Q(:"/("YU9(=25)X=Y?2J0AIK&;P&936IIC%(\F4]:EB
MZ)_K9^C*PR.(%V\]&D-R8!O/$,Q)R!FFY&18V<^&_P`;ED5#5U"3+38B<Z<I
MQB=X_!*[16;=$=C!".0/_JQ_6R9MC%C,Q,_D+[*1#<ECJ_\`<W-0O-,/&?DP
MP8A$6C5CXI_%CX\W<K4?3NG<ZE'>#+D*P#M!;!U%OQ2QT>Q#AC22LKA#8$A:
MITO6'RCI$B=2TN`PG*<"*`$>`B#2O7K>/;-VZ2(#V`D\2P8`$ER?`*]V[;LO
M=<R&!A1$LF=1`,HP#1B9R)E,QC$1C$DF1`8)P]645T#:Z6Y[TE:JJ3<[L5L\
M116N.NWVGK0S-8C'7A<Y1INGT0?F)B0R>+.*UQ;%2(M0T+B%YF2AE""(&<A%
M0&?CF\<<5:X@)&-,GI)(!9O:"/:I8]J;P-MAO!%@;5<R)6(W3?LB!NQC&<H/
M7S$91D26#%W41(;XX/'ND:J#B4MOG7=>E*Z@/P=(4!>FJ_5A.M/DA3((>Y3L
MF*R&OE[NV,QS2DB;*J/"PS(PY*:4E,($E,X!E8Y&=C'2:1:_\PL6/`R]G`L"
M6+'@53GVQO5L[A&=J(GM8?)&I;>V-2-EP!-[D=2<8U6ZP*@26(*.FQ,3'%V1
MGC499FJ.QR/-:!D8(^Q-R1H9&-E:DI2%K:&=J;R4Z!L:VU$0`DA.26`HDH`0
M`#@.,8VNU`(<>K7Q%:&=9-G,5]6/6TA@FH^,`3EL&I*@+#FE#WF@`D2'($G4
MSRMGAC5OQB)`=DA.8YEK3$Q&,%%"`7CAV(LS47B_TZUI.(?9TVEVI'5-8E<.
M)3S6LIU@ZCK4U$EUN^D%&DD22"P^;OY]=QN7)@'"Y#TG9PO";(LY)4E\0MY%
M/&;0J(V3#Y17T_C3+,H--F!VBLOB<D;DSNP22-OJ$YM>61Y;%A9J5>VN2!28
M4<48'(1@'G&<;$0=*,^GQ\8^GJ:FR:!5A92N(AG"*RFVAIA>UL2[3DUSII7$
M.+%)3:6>90?#96XQY6E)&@S("7<*49!0P!P844(!$ZEX>#WQ<:E+`D5HWUI<
M3VM.90_O\G='B8W!?SH22\2AR&[/QC$S#M4+#%4+@X#YF4;6E1HP8"$("@@`
M`(2)UZX\6.A>HJ/LG3?6U.OD0I2V@Q8N;09JNZ_\)3R(6X"=(XECCNHM(^10
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M.YQFT+K.:U6')H<&-5EYB;S9#I$)",+8Z'EDB7H%(DPC.83D!@0CP1`,^M8_
MH]]+W\\IE_R+6_L146-"7E5UX>-U[5K])U\R"%QEX6A<)-5;^G1S6HI0KP7D
MD:QTK^1E+69&[G$YP`3DW80NG`$(<*<!QC&Q%8+8?K4?(:A8"4+]IFT?/\A*
M(Y0G\EMN%F2*3L!Q@*E0QE6<L#@61;\B"4I+#G?NQP[$0GM=_P!0KY0/()%W
M>M[.N=NJRG'\D]*_5#I]9#ZUBTD0*!!YC7+'P;J]V#*V<TL&`FH%SR:W'?'(
MTV<_D(K+OT/>,8@_D=QC&[&)AICQC&/AC&,,5U[L8QL1/SY[?\^]+_(17/\`
M9Z=[:Y_$_P#S0?Z-;^[)?9;]1#_0R?\`CN7^2Q4(#^X;^_;_``<VP'\3^_\`
MO+;K^_?ZC_++IE;;E+\UZ6Q$MB);$2V(EL1+8B6Q%Y5:)&X$X3KTB5:G"H2*
MPD*R"E).%3>K(7H%."C@#!A0B7)BSB1[N(LTL(PYP(.,XX(!#'B%VA.=N55L
MF,F(<%BQ!!'#P()!]H)"&[&%!!GEWMM.`T`CR-`-09-*W_;!@R^+-$#.0Y^.
M<9#G\N-^,;0=O_,MS^A0_*37JN6#^A+"/A[RY/\`P>.MJU?LZC-K^/IDC+J5
M"AF:HI0F2.+:U-2D;:F^5[4&:L+:6UP),9RW!2C":608<0H*(,'S<DF\'!FK
MN4#KX<+9H_.#Q`'#ZJX[#D[<N!;FQ4=V3?@-K[DR,N!R`-GB3&4I"H]?A-5(
M&JD%B0)1,@*1*+N&6>-4MV0RCK6*+E#=(9;%=?C'I&8[3E#6RH`Q>`S&PZ\9
M$DTFQ3(Q!C`WN--$X&W@69;`(S%F$IZE*;O-*.L9[CF6\2Z!(&['-%D3(`:,
MI0\TF%+@2(=F=B1[<CL=G;!F[_A2E:E;PKW;4]RGCVY2.I>M6;\C:M5SU*;D
MK0F8B=0C7&$H^4QW[4--=3]&Z7]2DTS<$-S-8`]Q63U6X)FUBEKVR1-S4Q5O
M4PZTRE\1BS.]%.#R<X"3KD;:W+1-IQ8,&Y4DB4F5L^]N&'MV1=C=CK0E$PY2
M(B3$4S\H',EB(@TMQ)#J+[4V_M/N+N_:=OG@WA@9-NY;R(U3MPE=B+LA<QR+
MER43&&F\)3G'4!--$J`Y=C/DWJYSK*NGW45+I1+[8L2>JXE'62O:W;+$E<>9
MX+W=9%&J1&I$$(AT-KAP"-Y<'Q>@4K1H!$-^!FJ!@$HN,B=['N6K$K\I3N3D
M0!&(E("+L),(QC$^8R()9H\3SB-KQL'=K.7NF/MEFU@X6+:%VY.]?E9MSG>I
MC<E!S=NW;T6M0LPG&%0E=81!$8SLFI2]ISIGT06*DM9!&9E:>IUHI:SW-AC4
M$?&Z4QE;,K,APE99+JRJT#6]K$\*3*4ZIN`D3#5GC$%,(@0$X8ZWGYM[;L._
MJTWKN0(3($2X)F/$,[1#$,"2[-P677^T^WMO[K[@VNYB2O86'M$LJQ&<[T#;
MN"U8NL\9`R@#=E$QN52I`!D)/)?6T]5MUT8UZ]HLADB.R3M/"?34OKZR)@SL
MY*F(BU%NI4>D;38F(BULK$[@J!#@,HP=A"G,RSKB0K>,(<'F\Y&Y9F'#-MQF
M+DK&D8SD!Y=4L1.E@=,>?D#20X/BV?LW8.XKO;F9<M'$CN<L^-ZQ:E-KG0QK
MA*SJRG.)R2^.U<AJPD8,32'9NZ5ZFJ*T]:O)ZOMJ)K'*OZK*LVGAEIF*43*+
MJ&)C>5,E)G8CX-#X\^Q"1.S+@Q`(#40I3%B6$]2+!1`BKK,NY^#@Y-XW(RE"
MV)0Y&08<:O*`02''EX<0_`-"=NX/:O<?<VQ[;#"O0ADYFAE<9PLW!*<1#1^M
MN7(780FTP;AB3IRI\T@7)16K-'76#*:2)G(/2:G2''+73M"!OC!CY$9H[S][
MB&'MM6C;%*HQ*M;40#BD[B!8FZ@&1!#DO.2]KB.3>ENLL,3^JZ6,V8.)&1B[
MM[!R+J+N[+@6>Q;7<!L$9PWNYC5$SIN6H687:2*F<2DQE"DL6)?BHB5K:-Q1
M+0)HQM!NN>2N\MG]JZ46N;K9,UP-],?X]<=PQ.#S>/&'BBZ96D"XD2!6<6L"
M8)Q*5_`)_`'``QF)?RK>R8M^-TZLKMJIQ$U"=P1D.7!W+'FLRW?9MDROB9ON
MT3PK<=OL8NXRM1MFY`6YXV+=O6I@";$1,(@Q(H,>8<N9+,UC6E<5R:LXDU6J
M72:331-JMC$;0&1B,/S>[L;O7T5M&2SRP4\B"6X+X_+TS\N9&_HES42@+:SE
M.##5(1<J0C?OY67DV87=+IY0`X`N#$3,I/X%S$,0S$N_+%K^U[1L6P[-GY&'
MU\]VQ\FY,ZER!C*%Z[CV[5DPX"=LPA>G7&X9FY&#"'SO.U7+;2#5^&O)LN=T
MM82R9R:/5;(8B@A,NJN3F,%6G2-;54V<$H$]C5)=L<<FET>?QN532^-2?)9)
MA1@0$@ZQR\F.Z:%XD8TID0,1&4)-!Z)'Y\+D6,N+QD/M"K>V#9;O8YW7;HPE
MN]C'MSR+=TW;61;$\C3&19!>QDXMP2MVO)3<M7")2!!,C7:^M9$$/CVTO<0@
MAWZRF7=Q9QC?NI6W\_J_L8VFUYHN:1SBOZZ7^_#^WL1+G%?UTO\`?A_;V(ES
MBOZZ7^_#^WL1=!?Z'H010?R/<(L"_MPTQY^&<9^'8[LQO^'[.,_[VQ$^WGM.
M)^?).7S2^870];Y&#C#@0<#?9YP9$'?OQ@7#G=^ONVUT^)_#NASRZ:W]V2^S
M'ZA\9'X%S(!;UW+_`"6*A`<TOT-_"`_[;_\`##_W<_W=L`<:/[_[RVZIEZ[R
M/\Q_EETSMMRE^:U+8B6Q$MB);$2V(EL1+8B6Q%%%E^2KWU6=@^7?YE>:I[CV
MOT)[U;N>?U/<.F_MUZ'J>9_"_<<S?N^UM'1]*ZPTZ'7^+4ZGV?I-^TLRO>_G
MNY'J/4_=)A35J]+R#4O]54S<O,WR)RK']@O5U8^[/M7ZZ]0Y]G/7OI?U/ZK^
MZXO;COOYR]1<'#O[;^)Y>_?]G?M<7^CU(=3IZK^2IG?\%^+_`+'%0VW>O]'E
M>D]7Z?I_G.EJ:='AK4>6A^5?E?Y5IC'\H7HVX/3OR^^W_=77WZ[7Z`](]]W&
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MNP]$2($<9G1E&[*%HS,K35(@J"5!9>,%FC,WEP>Y'`%JQT8L'&ZZ-;$"-32>
MI@0_M?CRYOP]'[(CW&<W=?69;E'=?=J_T]49RN:;VJ#;KG&5(%-`BX,2>(`#
MSTKSY:_;::^W7M1[7=;*O<WMOI[TWW/H<>M?<KJ?NNY=IX>Y=X^^Z/@YWW7#
MM.X_I^A/I]+IW-;,S_2K^5N=7%N:\WW/WJ]4Q_5.L]6IMZ%5==+_`%6@W%JO
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MV[K_`,'UW'T_WW'M7N^GZ\=73ZAN#L[>#_)['X/RXJ-P/>[TB[Z?UGHNH:J:
M]+4854^&I2U='FI:KRLLDS_+=[M+>Q>UOO+W%YZ_MO8O5OJ'M)'?^IZ?[_U=
MZ;Y?5\7YR[5P\?X7=LAT'4FC3ZIR[-4[<7_"I9_&EO!4[_O3Z+'J>L]#IC35
M7IT5>1GX:=;T_B]1V\[IN]9GR&>@(S^D#^5+VO\`6!/H_P";CVH]#>O>S.W3
M^G?=S\Q>J_3_`%W!TWXOI.?N^[X]KU8XAP?[,_\`ZDW_`$)=B)?[,_\`ZDW_
M`$)=B)?[,_\`ZDW_`$)=B*?.BG]&WT5B?H[_`)+^W=9&O=;Y/?9?H^NY#SZ0
M]>^SWW/5=-W#MW7_`&N#J.3\.9L19J\_T?OKO/S)_*/[E]C;-_O3[1^M?3?.
M7]GW^M?SWV;G]3TW_(\?-X/CQ;8_N?NMU/\`;/0=72/X;2KI\/G\6YMX+V'L
M;]/?H9_1O[V>[FO/_EW7]/K-&O\`FWU>HU%7TFI?@R:?_P#(WHO_`.>_;NL_
M^O71]PZ?_F>LZ7_C\O\`8VC_`/L)O[II?^(YK+/_`*SU_P#R!U-'_5:J'^W3
'5]A_E7__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g342611ex99_1-pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g342611ex99_1-pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*0"J`P$1``(1`0,1`?_$`,(```("`P$!`0``````
M```````)"`H%!@<$"P(!`0`!!`,!`0`````````````#!`4&"`$'"0(*$```
M!@(!`@,#!`T("P`````"`P0%!@<!"`D`$A$3%"$5"F$R,U@Q02-4-3:V%S=7
MUQD:42)B-!88.)BA@M)3E-5VEBAX>1$``00!`@0#`P4($P```````0`"`P01
M$@4A,1,&05$B,A0'83,U%@AQP;(T5!55-X&1H;%2<I+2(U-STW2TU39V%QC_
MV@`,`P$``A$#$0`_`&][U<B&P^WG)?$N%'CJM(^D'MD9U,ZWGV_CC>A>YA3\
M":&]N>'JO*A"N+4MC7.#D+RW(%+QD!AR)Y>DB4H:4:5:9T1,DA'"9QHQ1F+3
MR;6UEN^;'E`$_75L-(I5=-Z2EW[,84R)WM2</+E)T3RL.\3<^[#6],2//@G)
M)!@(<$4`^01JW)X[7C4]AU@N2?RG2G8G>G2ZF)]&K"E\IF=LZHB?-A8"I,05
M3;CNY+IO(*#NV/-2B(O+#)UCJ-D-6E`;U04C@8C((K*O1$=$6BV97K-:T#DU
M>2!TF3(S2MO]VKW6OIQ+*VF:$KSR5(3X_.8,[L,LCBX)I`?NR)629D&1`%G(
M!"#DBJ[?#!JID1.>8N&3*S;,MDVK=]7>K&&76S-W^P)FKC5?J9W%F/#K(I&M
M7+U:K+>UEB-%W!"(S.<X#CQ\.B*V'T1'1$=$1T1<^F-IP2`R2KHA*W\AJDES
MS)R@-;-0B52A3)92SP.8V8YMY&$Q)P4Q:&%P)T6&'GY+(#A/@&1^884`9%J.
MR-ZQ[66C+*OF51Z62J/UG'A2!SC\':RWB4.9/K$B`!+8A/4HD^<`/6@&><::
M62F3!,.,%@!8NJ2_<CV^G)<E:YT<8R0T9)XXX?M_L#BL@[5[=M=V]PU.W*4L
M$-JW+H:^9VF-IP3EQ`)Y#``!+G$-`R5LM-V>SW75%=6]'VF1,+'94-C\U:6:
M7-8F23-B"1-J=R2HGQJ$8=Z-Q(*48"8$(S`9SCQ`(0<X%F2K8;;K,LL#@R1H
M<`1@@$9XCS5+ONT3]O[U:V.T^*2Q4G?$YT;M4;G,<6DL=@9:2.'`'S`*Z5U.
MK2CHB73RAR#8-CUD2(]7'F3,EV2ZWZJA,0.B1J-.[JQR21A1KD0E3@F5(D38
M)%@9BQ0:$)29*48:,00`%GK%>\9-U9LX9LKGLW*2>)C"W&?4[!Y@@#&23X`$
MK8'[--#X?W?B69?B?#7F[*J[5>L6!/J+`(8"YCL,<U[GZ\"-C3E[RUH!)`6K
MU@T*-&JP9K(WMW>GUE3EP)"2K+D+[Z*"%O8TP#E,?KV`1AE2R*8FH>[(1*58
M5AA@?`[)"4&>P-5LFTWZ$0?NEV:U;//)Q&WY&M`!/W79)\AR5C^*_P`0^S.[
M-SEJ_#[MG;-@[78\B(L8Z2Y*T'@^:6221K"X8/3A:T,SI+Y/:.>A_)!I;L,X
M_FO9;DD<(?Y$>6VL2QS1RFL5JUQ/%DM(4QRE4F3MA+@<;G&"2%!P,GCS@&"Q
MYS@.<@7325)R#S7<+3:R65FBV[D[F42FJ5<Z,+(Y/<5S8\33I32PY32MK1,A
M.%+2H\[M0N@22`*Q%FEB+",K(AD2_OW@V[?UF+,_XIE_Y-T1;7_?ZW0^LC9/
MXC^\?ZTS_P!>^^?P/]+_`*/DZ(H+?"!35XO/DIY(]@["4'.5GV#5JJ6OCBO%
MYC@)=9MZAE4K`,1N1'8Q[T;4H18Q[`X+"'V8QC'1%]#8XXE.2:H4&ED$$%C.
M//.&$HDDDH.1F&FF#R$!998`YR(6<XQC&/'/1$OFQ]R.+2Y(ZFB5D;C:13*.
MMDP@4[2M3CL_3&2$4SK":,%CP%^+&DGZ<\EQC$TC+>XI\]^`Y-3AP/`B\B"(
MB\VU>[+^S:2V[L?QV1&)\@UF1LU!$ZW@]&S1ALN./,\=WN/LRCWXZ0%\794-
ML%;Y&6\NZ%*I*7"0%=O>G";A0611%V)B')U1.AEB;3&<@AN-E:8HB17].:KD
M6NNNYNLKP\P2%*Y[,:?1-S1#DEPM3`=[M4M#>[AG"EP"9@M08(W&1%=$4X.,
MK<@[D"T0ULW`6Q1+!G>Z(.I=)'$V]6>M:V65QJ2OL(EB=F4J_%88QFR2,JC4
M.#LB/"D,+"8(0\"%DB1?\,W^F_G6_P#I_9_Y76=T1=Y2<ND>VWW:V=U[KW=>
MD]%-9],GY%6<RN"7O%*#N[9.\#5CZ@E3)3Z:]!O->Q2I*Q51Y0D<70;"].#J
MM&0),8E(-[L$7YU,Y:'UCY4C>,6S]D*OW;KRX:P%:NKVVU7HJ_2/:%_;T$I=
MI-0UWAIXP%3+Y*@984XK4#FU(F<W)6$H%"08UQ>4Y%WF8[^W1MUR,6AQJZ+R
M^-U*V:L0UMF6YNVK]#4%F.\4?Y`:B*B]&T7!'M03"U,]6#69$Z/K^!R;6T*5
M:0!N.4I?`TBZ$,_E-UUWIULKI`^.6\^C5W,<Q;KNM.P8C2M:6GJU,HPWJ'%D
M?P.]2LU81^60V8X-((*0'1E6L\\D\`5I8A$`$1)KW1;-SS_B7N.^G\[GB.;7
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MR:L5+725RXMS*+2.2%(0W.1^52E`12!U^W1W6UNYFD?%+MI=<;VWKR\];G#8
MJ@;T'54-IRU(BH8E$LPZ02=L=:)FJ`R!`)-`W?M5IV],H$(*0S&0X,.(`16+
MC4Y!PB!G$E&C3&^H3"-+`8).?Y1I'G$"%C.2C?(/&#N#X9[!BQ]C.>N"`>?@
MOIKW-!#20'#!QXC(.#YC(!^Z`J87)S;,IM/<RW$K^L4B9ZP?#*TAK0,T>4;.
MSL!*?#@<D(%GL+4/[T,]8>9C'<9@98<YR$LO&.5\J;^KW$!7NPFOU77*\7/.
MXXX6%',/BQB;8]&E;>W&^\%J/R$JA:'*HTKM28%@0\]WCGHBDF^\'D*E#LK?
MI-L_<,C?7#R?7/3\TQUW=EGIB"TR;"IQ<!J%9^$Z8H)9>!#S@``X#CPQC&.B
M+$_N'JM^L)97_:\1_P!CHBR_[C6L?U_6-^`?</XL1/Z'[X^;]+\GS>B*OEK=
M4_\`#^?$/34FVB,0G0WD2:I_"Z1NATSA+7<6=9Q+F&R8M#)/(3<%MT?=H!.F
MLR-'A5&`P6UNB1S-R6E,,&617V<9+.+QG&0'$G`\<9QVF%FEF!]F<9]H1@&'
M/RXSC/1%\[[XH2":T/G,1QB58Q1.N`262AJEBOZ/1]F841KK#YCL.R-41;)P
MF:R"?4*%[$-ZP66KQYV6\\&?H3"\Y(K;_*UOW6G#=H;*-@XW4+$\*4LBCM8U
M!5480H87$'.R):B<AL0'P3&A*)9HNRLD;5K5>4Y/G'D(<)2<EF&@,`109V<U
MV22+B<V)VPY(KU;;XNN5Z6V?8K"V2&1DP;4BE[!F]+/Z^O8;0U,)GA-!WM\9
MG]X0H&:1R/\`M%+G=T+*/3JR1'%)2R+KWPU4A8$O"OQ_L:E[:$ST^16[1,K.
MH<49#H\!9-@+3,>A-3>:<!6XA:"U)8E620#P1@P.1]N!8\2*%WPS8@_GRYV`
M=V.\/)]9PA!\<=V`BE]H8"+./LXP+(,^&?M^&>B+C7PN##FE[OY@M*KJ:T**
M_JLVQ3S]T99&A3B?'Z)OYDHCX9>U86%"/<HZJ&V(%Q:HOQ)&G?$AN,Y"I!D1
M%;:?9954!DE?19]=8A&)9:$@<XS6K$?AO1/<QD+/&'J8O+?'$)1>%BX]JBD>
M6KE0BP]A"8@0C!!QD/B15*N$X*_7;G[YT]<;@&:S6;>,W*V%K`+WG*51-ZU%
M9D\FB-R8#5.0X=P"BMUM)^0)\F>6%.IQG&/3&X`16Z)Y8\'K%L:'B>2-!&V^
M03"&U^Q&K?/,->)I8,D;HE#HVV)$A*A8N<WQ_=2"2P%EB[`Y$:9D!)9A@"*L
M/N;]P^+`XESCLX*)5:3WFD3&F9P`!ZHJ/;6&F)R1"SC!AX"S0BR''M\!8Z(F
MB\[!I0^'WD4`$TL0R=:9R6<$(PY$48-.B,``P.,^(!C+,"+&,^&<X%C/V\=$
M61X-<XSQ!<=GAG&?_%FLL>S.,^W#3C&<>S[>,X\,_P`F>B)3_P`(N8`>DFY`
M0#"+(>1V]N[`18%V]T"J`0?'P\<?S@^W'R=$7[V*S@'Q=F@F!9P')O'-9."\
M9SX9'G!6THLX#C/SO86+/^KG^3HB?CNSNK5&AE8PJZ;Q4"9ZJ?;IK.HIA,1G
MED(*]2V>Z*8^W3I\P,`LCC3`]"3"<Q!\!IT`S3\8%Y78(B5#R6\<L[M:<JMH
MM96]'8B.>M32ZS>&L+@WF.2]:2V)4R"<P@W)Y;?)&]^9B4^5"<D[)XC08/(P
M<$X>"R);U2Z;<A,Y>VN$1B#WI7K64?A$-TF3Q,JW@\:2X,\5!YHERYO`-.FP
M(0\IV].H4&9]@"Q"%T16:*AE%-:F*=:M&GRU54MO>Q8G.I%'&UV7+7J83!)"
M$9LFLJQ'@*I4M5L<3)=W$*-&-29V>:>2D)R9DHT19%7.YWY]/HQNM'FZ,SV<
MQIN'0L'5#;H[,)(Q-XU1DLL`!BH2%J<TB42DPLH(1&9!WB"`.,YSC&/#7_XF
M7+D'<@9!-*QGNL9PU[FC.J3C@$!>NWV&>W>W=U^#%BSNNWT+5D;]9:'S5X97
MZ1!5(;JD8YVD$D@9P"3PXE*6_.Y;?ZV;2_1?Y_Z1IG]-_OOPW]-_3^=\O6"_
MG#</RB?YO^L?_.6U?U-[._0^T_2F/Q.MR\OFN7R<E]!.^=>Z/VAK-]IS8>JX
M3<5823!0G>%SUB1OS.:I3X,]&Y)2U1>3FMZ;A&B$E7)1DK$H\]Q)H!>WK;I?
MG>4'8)Q3594C&G@],[/[\U/5#>0!"R5%%]MY^\0J+,Y?B$EAAJZP`32>PUD3
M%Y["$[6]I`)PXQ@KLZ(NMTSQGZ)4.]NDQ@^M%<.EEO[N3(I+<MH-ZJZKPD\B
M(,+/+?)!<]OK)O9CFX@4E!-!D;IV$C"'R@@P$.`D75]M-1=>]XZ-EFN>SM=M
M]EU1,,HE#@QJU;DU+VYW:CO4LTCCC^RJV][CLB9E7\].K2'E&8"(98^\DPTL
M9%%K7_B)TJU^B;'#"HM8UWL<1C;G#8(AV?N&QM@VJMH@[M1["NCE816QG]WA
M5;(C6%4:A\UC;$"OT1HD^3LDYR#HBU#7'A9TGU3C4JB5*F;&1=E>V:01B'EE
M;2WL6MHV)3"9L4^G$9U\=$$V0.5.(9])HPWG/REF-(<GHM($I8I.*$8`9%XM
M?^)K17CID\BO?6B#;&Q64O\`(6APFL>B.RFQ<S1VW(WIT4,#6IL"`RRUUD/L
M-8G<Y@>H]2]E'!2C-,5",!VB'B.63I,+\%W+@.).3C[ZJZ51UVR*S7QQY#CJ
M>=+0&M+R2<$\FG``))P`,E8*\]:=1]M]AUMSHH-LS2&VM$S.*Z^/VT>M4D25
M7;$>(F[#$Y.V1.:O$?D+XRV=67NB:MABD+RRO[>WA-$'M*`6=VTS+T;WOC:U
M^IDC6.X#@7!I'CRPX9(SA7NSVM<JU*]R::J(K522S#ZR"^.)\D;@,L`#]43P
MUCB"[`QG(S)#4G7VD&.83JUT,DO2[KP@,CF5"NUR;0S-3.["8430K97&1QBO
M$Q(&V"0*%R%3A"K4_P!G&AH]\"*)&NP<).3@J:"PR?7H!!8\M.?,?>X\%;-S
MVFSM7N_O!8X6:S)V%ISZ),@9X##@6D.'@1S*]>WG&WJYNC+*WM*RV*8PB_:9
M.--J'92CIT_5#?M=%G^J\]N8["BIY"IP8#O7J.YK=27%L\5)V<)\9.-R.=6Q
M9NIM%H'7DUC%E3ZW-B=GK`@0EAM<R396SBYLFKI<Y-2MB<WR&0J+QZ#5NU2Y
MP9%YZ(;Z)E-?`HE!Z<M6`A0>681:CNYQEZS;Z/U.3^UL69`;IU\?%+]2U_T-
M8;O4]TUV<X"(,<T#),6@M2`UI<3DI8QD*DR@)0PB$3DK)AV3"+2;#XA]/+<I
M4^@K/'L--:\D+F[2&TTSCM1L&VN]]RQ[-C9JZ77^\1RPF15;KZ3B(-I*'+QZ
MA,THD9*-`2F2%%D!(MJJ'C#U>UZU[E&L=1/FR=>T>_)6A.7&6C;[9A.;!6MC
M<W)Z-;JQDY]IF2.JF9Z5.A^79.PK&\AR*%@"D)@`AQARXGDN0"XX'$E<ZTEX
MO-)>/BS5R+4&O+\K=OET:7S>0>5?-[3+7^4.*@U''`&2&+RZS7^$O-D9;SP'
MHU!S:8K`B*R8!1CL#CJ(2@R",!Q!;JU8]//&,^9Y@>2K#2+:1N.DB#FS=,Q%
MV)?9+M>C'L#&DNSP<0,+`RS@_P!"YOL(BVQDR+9=QV5:<C"P7?\`WT=L$MC1
MA$(MS3@98M(TEP$+8W'DZ-Y5IRVY%DE$!.I-+P5V&#P*542@'\6LF`DX7YVC
M`8H.+2W;KXF":L4'+%1H"9;@H)BI6I&8H5*!A#XC,,$(8Q9SD6<YSG/1%18X
M]_B%.2OCDB;35U7V7'K8H]A`61'Z7OUD7SF*Q1&$8QB;X0^MSS'9Y#VK[J+(
M&](ZX:RAYR,*7`LBSDB9C:7QFO)7,8NI8JZIK5.GGM80(K,U;8O/IL]MHQ`R
M'"EE;)A.E<6+/`//<'"Y"X%>SV@%CHBPGPT&QEZ;6<]#+=^QMI2^X;6E="7I
M[[F<S<A+W`Q,DCS<%`U-J8L!#8PL#669D"-N0$)D*,O/824`/LZ(GF<_7^.&
M.?\`K]!/RNL/K7?XH_[F;_A8_P`*1>QWV"OU)6?^06?\O42@?V5]8#_=K;;_
M`%9?2VZW&7YNT=$1T1'1$=$1T1'1%#76F'V'&;AW(D<S@+S$F&U[MCT[K]T<
M'6(N!3Y&FFE:KKI0<<EC\D>7!H7Y?X8M&$A425G*7)1GCW#R`-KHQ31VK3Y6
M%K))0YI);Q`C8WP)(XM//P6==UW]LM[%L56C9CFLTMO?#,UK9`6/=;L3@9?&
MUKAHE9DM)]61X9/'8A2=K1VVDT[30"1MBERWCLR?/SVGF,;P2IH*54T]15(<
MM:R9D("AF<9R)J4C:0IAK`'H\+1$!,+"(5*RI999$S6$$VW.)U#YLQEO+5RU
M8.G&>&<95XM]P;-9V4[;)8C>UG;\,+&F)_"XRTV4X<8^#FP]1O4U!I#NF'%I
MPL`QT!<Y.O\`=3%)45M/^PLDI2WX.O?2+-86^&3NP'IZ=W*OYC$STSVQK$#E
ME4L)4(5S@)$?'FX0V_Q[0`+Q$VC;]QFC>)#>=#(TG6`USB26N'$'QR"<%H]/
MR*LL=R[%]9Z%NJ:<?;$6X5I6Q]!SI8H&,8V:*0%C@1@$/8S4)I,2^.5[[YH^
MVSJZ;872=920ES<J;LMZ#,!VD`V1Q6]G@,*6LB#">43X+,RN3TYMBE69)DF'
M0Y">F,3I?2A<5"H?-ZG:Z`BIQNU&%_JU\1(=..#G8!."=8R1@@8U$J'MW?\`
M9&[FZ_O]J,P-OP-Z0KX9)3;U0\Y9#J<UH<UH@=TPX.#GZ^DU@TNS8A85CVSM
M6QUQ&)JW6PZQ#5)YKN0&39.W-E*SIP*F1KI*73!<N.0-V6A"SE&.A3.F7%/Q
M*7T0L*`F]HH9XY[%JRR%CQ9+82TZL"-W')/JQPYD-R'`:>.5<]HN[7M6R[-9
MW6:N[9FS[@V=G2+G6H6F+3&W^CR[47$1F1S3$7=3TXX2,@-/STJ\[`E%FXL1
MZ/46M-'R$2)IF#,EK<^G)/`$#`QPM_90*$\D/#&U@#2LM`R!)<.Q8'<H>1F&
M#Q<(*LPMODGUN<97%I#O3H+<!I'/A_!QC5Z_%8IN6];:[M^M4VGW:-@I1,EC
M=&XSBU',7OE8_!8#(,'J`ZNF3"X8`"CW':3V/D$$,KZ70V6%#/X_IYK\_O$E
ML9F=&:17B0I1(HZY*2D\L<W%8D<$>3S4;^<1A2(DXP"C!(L8"*ACJ;@^+H3,
M?QHNB)+@09//VB>/@[&?/"RBUW!VI7W'\Y49H2&]S0W6-9"YKF5,$O:"8V@%
MIP'0@Z<@%FH<MS>*COY02E%4$9DE2.Q^AUAU0R.3O+6$EJB-XKGB,+H/ZQI9
M)?(0D."(3<Y&`>4:15A*%4#&3!9SY09S5N:0:S71R>Y.8"7#`DX:>`)\CZ@#
MC*ME?>.VHI',WF6*Y5^L4%ES61O)DJ!LHFPY\;"0[4P&)SFZM)X#F<Y:51S=
M_I].BIZNK"K:5&2!#(5<8D$H9I.Q.;XWUP\1@UHEK1FS"3@1IV4C3IC'>//+
M<\)WO)+^`1HTYIAWU9K3250VJQ\<N<D$@@G21APU\CRU-(<'8?X%1;-O>W5M
M]+]]LUK=$1%@D9&Z-[6.G;)JB=T,=1@RX1SQ/B=%JK$`.`$1?B"=,-E-]^,2
M1:\:UP)NFUT.]D4S*`Q-3-(Q&$04,5?`N,D&7*)LZQ]G."WE^/9YAP#C\8\0
M@R+/;U?&YTC5P=CBNLYM'5=TB3'J."1@D9X$@<LCP\%01_A8>;_ZI\6_S':[
M_M+ZY4:/X6'F_P#JGQ;_`#':[_M+Z(GC?#Q<%_)KH3R3Q+8?:2AF.OZF:ZDM
MF*KI&@N*H9HH*>Y2SHDK*EPQPV:/CX8%4H($')@4^2R\>T8@X\/$B<WRY\=N
MWFU6U#195'5HV2R%(J@B,4.=ED^@\:-]^MLAF;@O1X;9"^-SAD"=*[)Q8-P7
MDL>3,X#G.0BQCISOSM'?M[WMMW;(6R5^@QN2]C>(<\D8<X'Q"])?LE_:%^$O
MPM^%\_;?>^Y2U-Y?N\\X8VK9F'2?#78UVN*)[>+HWC3G(QDC!"71^YMY$/U*
M,?X@^X_TLU=^$_O?\:OF_P!/YGR]8A_U[W;^3-]C'SL?/^4MAO\`V#]GS]-3
M_2'5_$;OL>?S'[G/Y%=WZV27BHCHB.B(Z(CHB.B(Z(CHB.B(Z(CHB7A0/^/O
M>G_IK77\FI)UCU#Z>N_Q8OWBNT.Y?U:=N_VU[\.-,/ZR%=7HZ(CHB.B(Z(CH
+B.B(Z(CHB.B+_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g342611ex99_1-pg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g342611ex99_1-pg002.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*0"J`P$1``(1`0,1`?_$`,(```("`P$!`0``````
M```````)"`H%!@<$"P(!`0`!!`,!`0`````````````#!`4&"`$'"0(*$```
M!@(!`@,#!`T("P`````"`P0%!@<!"`D`$A$3%"$5"F$R,U@Q02-4-3:V%S=7
MUQD:42)B-!88.)BA@M)3E-5VEBAX>1$``00!`@0#`P4($P```````0`"`P01
M$@4A,1,&05$B,A0'83,U%@AQP;(T5!55-X&1H;%2<I+2(U-STW2TU39V%QC_
MV@`,`P$``A$#$0`_`&][U<B&P^WG)?$N%'CJM(^D'MD9U,ZWGV_CC>A>YA3\
M":&]N>'JO*A"N+4MC7.#D+RW(%+QD!AR)Y>DB4H:4:5:9T1,DA'"9QHQ1F+3
MR;6UEN^;'E`$_75L-(I5=-Z2EW[,84R)WM2</+E)T3RL.\3<^[#6],2//@G)
M)!@(<$4`^01JW)X[7C4]AU@N2?RG2G8G>G2ZF)]&K"E\IF=LZHB?-A8"I,05
M3;CNY+IO(*#NV/-2B(O+#)UCJ-D-6E`;U04C@8C((K*O1$=$6BV97K-:T#DU
M>2!TF3(S2MO]VKW6OIQ+*VF:$KSR5(3X_.8,[L,LCBX)I`?NR)629D&1`%G(
M!"#DBJ[?#!JID1.>8N&3*S;,MDVK=]7>K&&76S-W^P)FKC5?J9W%F/#K(I&M
M7+U:K+>UEB-%W!"(S.<X#CQ\.B*V'T1'1$=$1T1<^F-IP2`R2KHA*W\AJDES
MS)R@-;-0B52A3)92SP.8V8YMY&$Q)P4Q:&%P)T6&'GY+(#A/@&1^884`9%J.
MR-ZQ[66C+*OF51Z62J/UG'A2!SC\':RWB4.9/K$B`!+8A/4HD^<`/6@&><::
M62F3!,.,%@!8NJ2_<CV^G)<E:YT<8R0T9)XXX?M_L#BL@[5[=M=V]PU.W*4L
M$-JW+H:^9VF-IP3EQ`)Y#``!+G$-`R5LM-V>SW75%=6]'VF1,+'94-C\U:6:
M7-8F23-B"1-J=R2HGQJ$8=Z-Q(*48"8$(S`9SCQ`(0<X%F2K8;;K,LL#@R1H
M<`1@@$9XCS5+ONT3]O[U:V.T^*2Q4G?$YT;M4;G,<6DL=@9:2.'`'S`*Z5U.
MK2CHB73RAR#8-CUD2(]7'F3,EV2ZWZJA,0.B1J-.[JQR21A1KD0E3@F5(D38
M)%@9BQ0:$)29*48:,00`%GK%>\9-U9LX9LKGLW*2>)C"W&?4[!Y@@#&23X`$
MK8'[--#X?W?B69?B?#7F[*J[5>L6!/J+`(8"YCL,<U[GZ\"-C3E[RUH!)`6K
MU@T*-&JP9K(WMW>GUE3EP)"2K+D+[Z*"%O8TP#E,?KV`1AE2R*8FH>[(1*58
M5AA@?`[)"4&>P-5LFTWZ$0?NEV:U;//)Q&WY&M`!/W79)\AR5C^*_P`0^S.[
M-SEJ_#[MG;-@[78\B(L8Z2Y*T'@^:6221K"X8/3A:T,SI+Y/:.>A_)!I;L,X
M_FO9;DD<(?Y$>6VL2QS1RFL5JUQ/%DM(4QRE4F3MA+@<;G&"2%!P,GCS@&"Q
MYS@.<@7325)R#S7<+3:R65FBV[D[F42FJ5<Z,+(Y/<5S8\33I32PY32MK1,A
M.%+2H\[M0N@22`*Q%FEB+",K(AD2_OW@V[?UF+,_XIE_Y-T1;7_?ZW0^LC9/
MXC^\?ZTS_P!>^^?P/]+_`*/DZ(H+?"!35XO/DIY(]@["4'.5GV#5JJ6OCBO%
MYC@)=9MZAE4K`,1N1'8Q[T;4H18Q[`X+"'V8QC'1%]#8XXE.2:H4&ED$$%C.
M//.&$HDDDH.1F&FF#R$!998`YR(6<XQC&/'/1$OFQ]R.+2Y(ZFB5D;C:13*.
MMDP@4[2M3CL_3&2$4SK":,%CP%^+&DGZ<\EQC$TC+>XI\]^`Y-3AP/`B\B"(
MB\VU>[+^S:2V[L?QV1&)\@UF1LU!$ZW@]&S1ALN./,\=WN/LRCWXZ0%\794-
ML%;Y&6\NZ%*I*7"0%=O>G";A0611%V)B')U1.AEB;3&<@AN-E:8HB17].:KD
M6NNNYNLKP\P2%*Y[,:?1-S1#DEPM3`=[M4M#>[AG"EP"9@M08(W&1%=$4X.,
MK<@[D"T0ULW`6Q1+!G>Z(.I=)'$V]6>M:V65QJ2OL(EB=F4J_%88QFR2,JC4
M.#LB/"D,+"8(0\"%DB1?\,W^F_G6_P#I_9_Y76=T1=Y2<ND>VWW:V=U[KW=>
MD]%-9],GY%6<RN"7O%*#N[9.\#5CZ@E3)3Z:]!O->Q2I*Q51Y0D<70;"].#J
MM&0),8E(-[L$7YU,Y:'UCY4C>,6S]D*OW;KRX:P%:NKVVU7HJ_2/:%_;T$I=
MI-0UWAIXP%3+Y*@984XK4#FU(F<W)6$H%"08UQ>4Y%WF8[^W1MUR,6AQJZ+R
M^-U*V:L0UMF6YNVK]#4%F.\4?Y`:B*B]&T7!'M03"U,]6#69$Z/K^!R;6T*5
M:0!N.4I?`TBZ$,_E-UUWIULKI`^.6\^C5W,<Q;KNM.P8C2M:6GJU,HPWJ'%D
M?P.]2LU81^60V8X-((*0'1E6L\\D\`5I8A$`$1)KW1;-SS_B7N.^G\[GB.;7
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MR:L5+725RXMS*+2.2%(0W.1^52E`12!U^W1W6UNYFD?%+MI=<;VWKR\];G#8
MJ@;T'54-IRU(BH8E$LPZ02=L=:)FJ`R!`)-`W?M5IV],H$(*0S&0X,.(`16+
MC4Y!PB!G$E&C3&^H3"-+`8).?Y1I'G$"%C.2C?(/&#N#X9[!BQ]C.>N"`>?@
MOIKW-!#20'#!QXC(.#YC(!^Z`J87)S;,IM/<RW$K^L4B9ZP?#*TAK0,T>4;.
MSL!*?#@<D(%GL+4/[T,]8>9C'<9@98<YR$LO&.5\J;^KW$!7NPFOU77*\7/.
MXXX6%',/BQB;8]&E;>W&^\%J/R$JA:'*HTKM28%@0\]WCGHBDF^\'D*E#LK?
MI-L_<,C?7#R?7/3\TQUW=EGIB"TR;"IQ<!J%9^$Z8H)9>!#S@``X#CPQC&.B
M+$_N'JM^L)97_:\1_P!CHBR_[C6L?U_6-^`?</XL1/Z'[X^;]+\GS>B*OEK=
M4_\`#^?$/34FVB,0G0WD2:I_"Z1NATSA+7<6=9Q+F&R8M#)/(3<%MT?=H!.F
MLR-'A5&`P6UNB1S-R6E,,&617V<9+.+QG&0'$G`\<9QVF%FEF!]F<9]H1@&'
M/RXSC/1%\[[XH2":T/G,1QB58Q1.N`262AJEBOZ/1]F841KK#YCL.R-41;)P
MF:R"?4*%[$-ZP66KQYV6\\&?H3"\Y(K;_*UOW6G#=H;*-@XW4+$\*4LBCM8U
M!5480H87$'.R):B<AL0'P3&A*)9HNRLD;5K5>4Y/G'D(<)2<EF&@,`109V<U
MV22+B<V)VPY(KU;;XNN5Z6V?8K"V2&1DP;4BE[!F]+/Z^O8;0U,)GA-!WM\9
MG]X0H&:1R/\`M%+G=T+*/3JR1'%)2R+KWPU4A8$O"OQ_L:E[:$ST^16[1,K.
MH<49#H\!9-@+3,>A-3>:<!6XA:"U)8E620#P1@P.1]N!8\2*%WPS8@_GRYV`
M=V.\/)]9PA!\<=V`BE]H8"+./LXP+(,^&?M^&>B+C7PN##FE[OY@M*KJ:T**
M_JLVQ3S]T99&A3B?'Z)OYDHCX9>U86%"/<HZJ&V(%Q:HOQ)&G?$AN,Y"I!D1
M%;:?9954!DE?19]=8A&)9:$@<XS6K$?AO1/<QD+/&'J8O+?'$)1>%BX]JBD>
M6KE0BP]A"8@0C!!QD/B15*N$X*_7;G[YT]<;@&:S6;>,W*V%K`+WG*51-ZU%
M9D\FB-R8#5.0X=P"BMUM)^0)\F>6%.IQG&/3&X`16Z)Y8\'K%L:'B>2-!&V^
M03"&U^Q&K?/,->)I8,D;HE#HVV)$A*A8N<WQ_=2"2P%EB[`Y$:9D!)9A@"*L
M/N;]P^+`XESCLX*)5:3WFD3&F9P`!ZHJ/;6&F)R1"SC!AX"S0BR''M\!8Z(F
MB\[!I0^'WD4`$TL0R=:9R6<$(PY$48-.B,``P.,^(!C+,"+&,^&<X%C/V\=$
M61X-<XSQ!<=GAG&?_%FLL>S.,^W#3C&<>S[>,X\,_P`F>B)3_P`(N8`>DFY`
M0#"+(>1V]N[`18%V]T"J`0?'P\<?S@^W'R=$7[V*S@'Q=F@F!9P')O'-9."\
M9SX9'G!6THLX#C/SO86+/^KG^3HB?CNSNK5&AE8PJZ;Q4"9ZJ?;IK.HIA,1G
MED(*]2V>Z*8^W3I\P,`LCC3`]"3"<Q!\!IT`S3\8%Y78(B5#R6\<L[M:<JMH
MM96]'8B.>M32ZS>&L+@WF.2]:2V)4R"<P@W)Y;?)&]^9B4^5"<D[)XC08/(P
M<$X>"R);U2Z;<A,Y>VN$1B#WI7K64?A$-TF3Q,JW@\:2X,\5!YHERYO`-.FP
M(0\IV].H4&9]@"Q"%T16:*AE%-:F*=:M&GRU54MO>Q8G.I%'&UV7+7J83!)"
M$9LFLJQ'@*I4M5L<3)=W$*-&-29V>:>2D)R9DHT19%7.YWY]/HQNM'FZ,SV<
MQIN'0L'5#;H[,)(Q-XU1DLL`!BH2%J<TB42DPLH(1&9!WB"`.,YSC&/#7_XF
M7+D'<@9!-*QGNL9PU[FC.J3C@$!>NWV&>W>W=U^#%BSNNWT+5D;]9:'S5X97
MZ1!5(;JD8YVD$D@9P"3PXE*6_.Y;?ZV;2_1?Y_Z1IG]-_OOPW]-_3^=\O6"_
MG#</RB?YO^L?_.6U?U-[._0^T_2F/Q.MR\OFN7R<E]!.^=>Z/VAK-]IS8>JX
M3<5823!0G>%SUB1OS.:I3X,]&Y)2U1>3FMZ;A&B$E7)1DK$H\]Q)H!>WK;I?
MG>4'8)Q3594C&G@],[/[\U/5#>0!"R5%%]MY^\0J+,Y?B$EAAJZP`32>PUD3
M%Y["$[6]I`)PXQ@KLZ(NMTSQGZ)4.]NDQ@^M%<.EEO[N3(I+<MH-ZJZKPD\B
M(,+/+?)!<]OK)O9CFX@4E!-!D;IV$C"'R@@P$.`D75]M-1=>]XZ-EFN>SM=M
M]EU1,,HE#@QJU;DU+VYW:CO4LTCCC^RJV][CLB9E7\].K2'E&8"(98^\DPTL
M9%%K7_B)TJU^B;'#"HM8UWL<1C;G#8(AV?N&QM@VJMH@[M1["NCE816QG]WA
M5;(C6%4:A\UC;$"OT1HD^3LDYR#HBU#7'A9TGU3C4JB5*F;&1=E>V:01B'EE
M;2WL6MHV)3"9L4^G$9U\=$$V0.5.(9])HPWG/REF-(<GHM($I8I.*$8`9%XM
M?^)K17CID\BO?6B#;&Q64O\`(6APFL>B.RFQ<S1VW(WIT4,#6IL"`RRUUD/L
M-8G<Y@>H]2]E'!2C-,5",!VB'B.63I,+\%W+@.).3C[ZJZ51UVR*S7QQY#CJ
M>=+0&M+R2<$\FG``))P`,E8*\]:=1]M]AUMSHH-LS2&VM$S.*Z^/VT>M4D25
M7;$>(F[#$Y.V1.:O$?D+XRV=67NB:MABD+RRO[>WA-$'M*`6=VTS+T;WOC:U
M^IDC6.X#@7!I'CRPX9(SA7NSVM<JU*]R::J(K522S#ZR"^.)\D;@,L`#]43P
MUCB"[`QG(S)#4G7VD&.83JUT,DO2[KP@,CF5"NUR;0S-3.["8430K97&1QBO
M$Q(&V"0*%R%3A"K4_P!G&AH]\"*)&NP<).3@J:"PR?7H!!8\M.?,?>X\%;-S
MVFSM7N_O!8X6:S)V%ISZ),@9X##@6D.'@1S*]>WG&WJYNC+*WM*RV*8PB_:9
M.--J'92CIT_5#?M=%G^J\]N8["BIY"IP8#O7J.YK=27%L\5)V<)\9.-R.=6Q
M9NIM%H'7DUC%E3ZW-B=GK`@0EAM<R396SBYLFKI<Y-2MB<WR&0J+QZ#5NU2Y
MP9%YZ(;Z)E-?`HE!Z<M6`A0>681:CNYQEZS;Z/U.3^UL69`;IU\?%+]2U_T-
M8;O4]TUV<X"(,<T#),6@M2`UI<3DI8QD*DR@)0PB$3DK)AV3"+2;#XA]/+<I
M4^@K/'L--:\D+F[2&TTSCM1L&VN]]RQ[-C9JZ77^\1RPF15;KZ3B(-I*'+QZ
MA,THD9*-`2F2%%D!(MJJ'C#U>UZU[E&L=1/FR=>T>_)6A.7&6C;[9A.;!6MC
M<W)Z-;JQDY]IF2.JF9Z5.A^79.PK&\AR*%@"D)@`AQARXGDN0"XX'$E<ZTEX
MO-)>/BS5R+4&O+\K=OET:7S>0>5?-[3+7^4.*@U''`&2&+RZS7^$O-D9;SP'
MHU!S:8K`B*R8!1CL#CJ(2@R",!Q!;JU8]//&,^9Y@>2K#2+:1N.DB#FS=,Q%
MV)?9+M>C'L#&DNSP<0,+`RS@_P!"YOL(BVQDR+9=QV5:<C"P7?\`WT=L$MC1
MA$(MS3@98M(TEP$+8W'DZ-Y5IRVY%DE$!.I-+P5V&#P*542@'\6LF`DX7YVC
M`8H.+2W;KXF":L4'+%1H"9;@H)BI6I&8H5*!A#XC,,$(8Q9SD6<YSG/1%18X
M]_B%.2OCDB;35U7V7'K8H]A`61'Z7OUD7SF*Q1&$8QB;X0^MSS'9Y#VK[J+(
M&](ZX:RAYR,*7`LBSDB9C:7QFO)7,8NI8JZIK5.GGM80(K,U;8O/IL]MHQ`R
M'"EE;)A.E<6+/`//<'"Y"X%>SV@%CHBPGPT&QEZ;6<]#+=^QMI2^X;6E="7I
M[[F<S<A+W`Q,DCS<%`U-J8L!#8PL#669D"-N0$)D*,O/824`/LZ(GF<_7^.&
M.?\`K]!/RNL/K7?XH_[F;_A8_P`*1>QWV"OU)6?^06?\O42@?V5]8#_=K;;_
M`%9?2VZW&7YNT=$1T1'1$=$1T1'1%#76F'V'&;AW(D<S@+S$F&U[MCT[K]T<
M'6(N!3Y&FFE:KKI0<<EC\D>7!H7Y?X8M&$A425G*7)1GCW#R`-KHQ31VK3Y6
M%K))0YI);Q`C8WP)(XM//P6==UW]LM[%L56C9CFLTMO?#,UK9`6/=;L3@9?&
MUKAHE9DM)]61X9/'8A2=K1VVDT[30"1MBERWCLR?/SVGF,;P2IH*54T]15(<
MM:R9D("AF<9R)J4C:0IAK`'H\+1$!,+"(5*RI999$S6$$VW.)U#YLQEO+5RU
M8.G&>&<95XM]P;-9V4[;)8C>UG;\,+&F)_"XRTV4X<8^#FP]1O4U!I#NF'%I
MPL`QT!<Y.O\`=3%)45M/^PLDI2WX.O?2+-86^&3NP'IZ=W*OYC$STSVQK$#E
ME4L)4(5S@)$?'FX0V_Q[0`+Q$VC;]QFC>)#>=#(TG6`USB26N'$'QR"<%H]/
MR*LL=R[%]9Z%NJ:<?;$6X5I6Q]!SI8H&,8V:*0%C@1@$/8S4)I,2^.5[[YH^
MVSJZ;872=920ES<J;LMZ#,!VD`V1Q6]G@,*6LB#">43X+,RN3TYMBE69)DF'
M0Y">F,3I?2A<5"H?-ZG:Z`BIQNU&%_JU\1(=..#G8!."=8R1@@8U$J'MW?\`
M9&[FZ_O]J,P-OP-Z0KX9)3;U0\Y9#J<UH<UH@=TPX.#GZ^DU@TNS8A85CVSM
M6QUQ&)JW6PZQ#5)YKN0&39.W-E*SIP*F1KI*73!<N.0-V6A"SE&.A3.F7%/Q
M*7T0L*`F]HH9XY[%JRR%CQ9+82TZL"-W')/JQPYD-R'`:>.5<]HN[7M6R[-9
MW6:N[9FS[@V=G2+G6H6F+3&W^CR[47$1F1S3$7=3TXX2,@-/STJ\[`E%FXL1
MZ/46M-'R$2)IF#,EK<^G)/`$#`QPM_90*$\D/#&U@#2LM`R!)<.Q8'<H>1F&
M#Q<(*LPMODGUN<97%I#O3H+<!I'/A_!QC5Z_%8IN6];:[M^M4VGW:-@I1,EC
M=&XSBU',7OE8_!8#(,'J`ZNF3"X8`"CW':3V/D$$,KZ70V6%#/X_IYK\_O$E
ML9F=&:17B0I1(HZY*2D\L<W%8D<$>3S4;^<1A2(DXP"C!(L8"*ACJ;@^+H3,
M?QHNB)+@09//VB>/@[&?/"RBUW!VI7W'\Y49H2&]S0W6-9"YKF5,$O:"8V@%
MIP'0@Z<@%FH<MS>*COY02E%4$9DE2.Q^AUAU0R.3O+6$EJB-XKGB,+H/ZQI9
M)?(0D."(3<Y&`>4:15A*%4#&3!9SY09S5N:0:S71R>Y.8"7#`DX:>`)\CZ@#
MC*ME?>.VHI',WF6*Y5^L4%ES61O)DJ!LHFPY\;"0[4P&)SFZM)X#F<Y:51S=
M_I].BIZNK"K:5&2!#(5<8D$H9I.Q.;XWUP\1@UHEK1FS"3@1IV4C3IC'>//+
M<\)WO)+^`1HTYIAWU9K3250VJQ\<N<D$@@G21APU\CRU-(<'8?X%1;-O>W5M
M]+]]LUK=$1%@D9&Z-[6.G;)JB=T,=1@RX1SQ/B=%JK$`.`$1?B"=,-E-]^,2
M1:\:UP)NFUT.]D4S*`Q-3-(Q&$04,5?`N,D&7*)LZQ]G."WE^/9YAP#C\8\0
M@R+/;U?&YTC5P=CBNLYM'5=TB3'J."1@D9X$@<LCP\%01_A8>;_ZI\6_S':[
M_M+ZY4:/X6'F_P#JGQ;_`#':[_M+Z(GC?#Q<%_)KH3R3Q+8?:2AF.OZF:ZDM
MF*KI&@N*H9HH*>Y2SHDK*EPQPV:/CX8%4H($')@4^2R\>T8@X\/$B<WRY\=N
MWFU6U#195'5HV2R%(J@B,4.=ED^@\:-]^MLAF;@O1X;9"^-SAD"=*[)Q8-P7
MDL>3,X#G.0BQCISOSM'?M[WMMW;(6R5^@QN2]C>(<\D8<X'Q"])?LE_:%^$O
MPM^%\_;?>^Y2U-Y?N\\X8VK9F'2?#78UVN*)[>+HWC3G(QDC!"71^YMY$/U*
M,?X@^X_TLU=^$_O?\:OF_P!/YGR]8A_U[W;^3-]C'SL?/^4MAO\`V#]GS]-3
M_2'5_$;OL>?S'[G/Y%=WZV27BHCHB.B(Z(CHB.B(Z(CHB.B(Z(CHB7A0/^/O
M>G_IK77\FI)UCU#Z>N_Q8OWBNT.Y?U:=N_VU[\.-,/ZR%=7HZ(CHB.B(Z(CH
+B.B(Z(CHB.B+_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
